In 2018, Steven Paul, M.D. earned $404.75K in total compensation at Voyager Therapeutics, Inc., primarily from $298.29K salary. Most recently sold 15,000 shares in Apr 2022. Currently holds stock worth $83.65M. Led Voyager Therapeutics, Inc. as CEO for 3 years.
Compensation History
Annual executive compensation data for Steven Paul, M.D., including salary, bonuses, and stock awards.
Year
2018
Total Compensation
$404.75K
Salary
$298.29K
Bonus
$0.00
Other
$106.45K
Salary
$298.29KBoard Justification
The compensation philosophy is designed to attract and retain talented executives while aligning their incentives with the company's performance and long-term shareholder interests.
Bonus
$0.00Board Justification
No bonus was awarded for the year 2018 as he transitioned to a non-employee director role.
Other Compensation
$106.45KBoard Justification
This includes reimbursement of business or economy round trip tickets to and from Dr. Paul's principal residence in Indiana annually, as well as consulting services paid pursuant to his consulting agreement with the company after his transition from CEO.
Restricted Stock
Board Justification
No stock was vested in 2018 as all stock options were granted in previous years and not vested in 2018.
Performance Metrics
Performance metrics for 2018 were based on corporate goals achieved at a rate of 105%.
Steven Paul, M.D.
Ex-CEO of Voyager Therapeutics, Inc.
Education
B.A. in Biology and Psychology from Tulane University, M.S. and M.D. from Tulane University School of Medicine
Field of Expertise
Healthcare & Life Sciences - Medicine
Sector of Economy
Healthcare
Born
January 1, 1951 - 74 years ago
CEO of Voyager Therapeutics, Inc. for
3 years 10 months (Sep 2014 - Jul 2018)
Previous Experience
Executive Vice President, President of Lilly Research Laboratories at Eli Lilly and Company
Other Voyager Therapeutics, Inc. CEOs
Holdings
Track Steven Paul, M.D.'s stock holdings and portfolio value over time.
Total Stock Sold
$45.47M
$1.08M
20,000 BFAM shares
$35.77M
282,043 SAGE shares
$8.62M
60,000 ALNY shares
What if they kept their stock?
If Steven Paul, M.D. didn't sell their stock, today they would have:
Extra BFAM20,000 shares worth $2.06M and SAGE282,043 shares worth $0.00 and ALNY60,000 shares worth $27.49M.
This is -35.01% and $15.92M less than what they got when they sold the stock.
Charitable Transactions
614,115 shares
SAGE
Recent Charitable Transactions
122,400 shares
SAGE
Feb 25, 2019
Charity
241,695 shares
SAGE
Feb 15, 2019
Charity
244,939 shares
SAGE
Dec 31, 2018
Charity
5,081 shares
SAGE
Feb 23, 2016
Charity
Insider Trading
Steven Paul, M.D.'s recent stock transactions, purchases, and sales filed with the SEC.
$2.59M
ALNY at $172.80/share
Apr 1, 2022
Sale
$2.10M
ALNY at $140.00/share
Dec 18, 2020
Sale
$3.90M
ALNY at $130.00/share
Feb 10, 2020
Sale
$1.27M
SAGE at $161.04/share
Mar 21, 2019
Sale
$9.74M
SAGE at $161.17/share
Mar 18, 2019
Sale
$418.60K
SAGE at $161.00/share
Mar 1, 2019
Sale
$322.00K
SAGE at $161.00/share
Feb 25, 2019
Sale
122,400 shares
SAGE
Feb 25, 2019
Charity
122,400 shares
SAGE
Feb 25, 2019
Charity
$8.23M
SAGE at $161.38/share
Feb 15, 2019
Sale
Rivals
Compare Steven Paul, M.D. with competitor CEOs and industry peers.